Japan Foreign Investment in Japan Stocks up to ¥603.7B in July 5 from previous ¥185.3B
Jul 10, 2024 11:50 PM
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Hims & Hers: A Game-Changer in Telehealth or Just Another Fad?
Explore the exciting world of Hims & Hers (NYSE: HIMS) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!The Motley Fool
an hour ago
From Ozempic to Wegovy: Growth and Risks Behind Novo Nordisk’s Q2 Performance
TradingKey - Novo Nordisk achieved revenue of $11.67 billion in Q2 of the 2025 fiscal year, a 19% increase year-over-year, but it fell short of market expectations. Growth was primarily driven by strong performance in obesity care and rare diseases.TradingKey
17 hours ago
MP Materials 2Q25 Earnings Preview: The New Stock Darling?
TradingKey - MP Materials will release its earnings for the second quarter of the fiscal 2025 on August 7th after the bell.TradingKey
Tue, Aug 5
Bank of England August Rate Decision Preview: Pound Likely to Enter a Fluctuation Phase
TradingKey - On 7 August 2025, the Bank of England (BoE) will announce its policy interest rate decision. The prevailing market view suggests a high likelihood of a 25-basis-point rate cut, lowering the benchmark rate from the current 4.25% to 4%.TradingKey
Mon, Aug 4
Eli Lilly FY2025 Second Quarter Earnings Preview
TradingKey - Eli Lilly’s Q2 2025 earnings report is expected to be released before the U.S. stock market opens on August 7. Mounjaro and Zepbound are the core drivers of Eli Lilly’s revenue growth, with GLP-1 receptor agonist drugs performing strongly in the diabetes and weight-loss markets.TradingKey
Mon, Aug 4
.jpg)
